Development of new biomarkers for small intestinal malabsorption
Project/Area Number |
24614016
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Integrated Nutrition Science
|
Research Institution | Tokyo Medical University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
HONDA Akira 東京医科大学, 医学部, 教授 (10468639)
MIYAZAKI Teruo 東京医科大学, 医学部, 講師 (60532687)
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
|
Keywords | クローン病 / 小腸機能 / LC-MS/MS / CYP3A4 / 胆汁酸 |
Outline of Final Research Achievements |
To explore new biomarkers for small intestinal malabsorption, we determined serum concentrations of cholesterol related compounds in patients with CD or ulcerative colitis (UC). The concentrations of 7α-hydroxy-4-cholesten-3-one (C4), a marker for bile acid synthesis, and lathosterol, a marker for cholesterol biosynthesis, were significantly elevated while the levels of fibroblast growth factor 19 (FGF19), a marker for intestinal bile acid flux, and 4β-hydroxycholesterol (4β-HC), a known marker for CYP3A4 activity, were reduced in CD patients compared with UC patients and controls. These changes were more evident in ileal-resected CD patients. In contrast, serum plant sterols, markers for intestinal cholesterol absorption, were not significantly changed in all CD patients. These results showed that serum C4, FGF19, lathosterol and 4β-HC were good biomarkers for ileal malabsorption, which can be used for differential diagnosis of ileal diseases from jejunal or colorectal diseases.
|
Report
(4 results)
Research Products
(5 results)